Previous Article | Next Article ![]()
Molecular and Cellular Biology, April 2000, p. 2317-2325, Vol. 20, No. 7
Department of Medical Biochemistry and
Microbiology, BMC, Uppsala University, S-751 23 Uppsala, Sweden
Received 25 August 1999/Returned for modification 5 October
1999/Accepted 30 December 1999
Splicing of the adenovirus IIIa pre-mRNA is subjected to a temporal
regulation, such that efficient IIIa 3' splice site usage is confined
to the late phase of the infectious cycle. Here we show that IIIa
pre-mRNA splicing is activated more than 200-fold in nuclear extracts
prepared from late adenovirus-infected cells (Ad-NE) compared to
uninfected HeLa cell nuclear extracts (HeLa-NE). In contrast, splicing
of the
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
A Novel Type of Splicing Enhancer Regulating
Adenovirus Pre-mRNA Splicing


-globin pre-mRNA is repressed in Ad-NE. We constructed hybrid
pre-mRNAs between IIIa and
-globin in order to identify the minimal
IIIa sequence element conferring enhanced splicing in Ad-NE. Using this
approach, we show that the IIIa branch site/pyrimidine tract functions
as a Janus element: it blocks splicing in HeLa-NE and functions as a
splicing enhancer in Ad-NE. Therefore, we named this sequence the IIIa
virus infection-dependent splicing enhancer (3VDE). This element is
essential for regulated IIIa pre-mRNA splicing in Ad-NE and sufficient
to confer an enhanced splicing phenotype to the
-globin pre-mRNA in
Ad-NE. We further show that the increase in IIIa splicing observed in
Ad-NE is not accompanied by a similar increase in U2AF binding to the
IIIa pyrimidine tract. This finding suggests that splicing activation by the 3VDE may operate without efficient U2AF interaction with the
pre-mRNA. Importantly, this report represents the first description of
a splicing enhancer that has evolved to function selectively in the
context of a virus infection, a finding that adds a new level at which
viruses may subvert the host cell RNA biosynthetic machinery to
facilitate their own replication.
*
Corresponding author. Mailing address: Department of
Medical Biochemistry and Microbiology, BMC, Uppsala University, Box
582, S-751 23 Uppsala, Sweden. Phone: 46-18-471 4164. Fax: 46-18-509 876. E-mail: goran.akusjarvi{at}imim.uu.se.
Present address: Institute of Cell Biology, University of Berne,
3012 Bern, Switzerland.
Permanent address: Henan Bioproduct Institute, Zhengzhou 450053, People's Republic of China.
§
Present address: MRC LMB, Cambridge CB2 2QH, England.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»